Detecting tumor DNA in blood and urine of people with early bladder cancer
Checks for tumor DNA in urine and blood of adults with early bladder cancer.
Plain-language title generated from the registry record
Registry title: T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer
Key facts
- Where
- Basel and Lucerne, SwitzerlandSee the 2 sites
Where in Switzerland
- Universitätsspital BaselBasel, SwitzerlandTaking people
- Luzerner KantonsspitalLucerne, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT07581496
- Record updated
- 18 May 2026
- Original description
T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality.Read full original descriptionShow less
T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer
T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality.
Current risk stratification is insufficient and needs improvement. Ct-DNA could identify patients with disease persistence, progression and could monitor and tailor therapy. It might improve patient risk stratification, avoiding under- and overtreatment, reducing morbidity and mortality.
Primary objective is to investigate the detectability of ct-DNA in T1G3 urothelial bladder cancer patients and build a biobank through collection of different sample types (urine, plasma) in T1G3 bladder cancer patients which allows future retrospective testing.
Inclusion: patients > 18 years of age, able to give informed consent as documented by signature,; patients with a cystoscopically proven bladder cancer, suspicious for T1 stage, who will undergo TUR-B.
Exclusion: Patients with metastases or concomitant upper tract tumor at diagnosis will; Patients with non T1 G3 cancers; Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc; Vulnerable persons (e.g. < 18y of age, unable to consent to the study); Patients with upstaging, either at re-TUR-B or after immediate radical cystectomy.